Business Inquiry

Global：

Email:marketing@medicilon.com

+1(781)535-1428(U.S.)

0044 7790 816 954 (Europe)

China：

Email: marketing@medicilon.com.cn

Tel: +86 (21) 5859-1500

This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or refuse these technologies

CAR-T has shown promising clinical results in the treatment of leukemia and lymphoma. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon

2023-07-11

Page View：

Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon.

Reference:

Jing-E Zhou, et al. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. Biomed Pharmacother. 2021 May;137:111339. doi: 10.1016/j.biopha.2021.111339.

CAR-T immunotherapy leukemia lymphoma PD-1 plasmids-sequenced

Return

Relevant News

Immune checkpoint blockade therapies have changed the paradigm of cancer therapies. In vivo studies for anti-PD-1 antibody across 23 syngeneic tumor models were performed by Medicilon

2023-07-11

Immune checkpoint blockade therapies have changed the paradigm of cancer therapies. Reseachers performed in vivo screening for anti-PD-1 therapy across 23 syngeneic tumor models and found that CT-26 and Colon 26, which are murine colorectal carcinoma derived from BALB/c mice, showed different sensitivity to anti-PD-1. In vivo studies for anti-PD-1 antibody across 23 syngeneic tumor models were performed by Medicilon.

XY153 is a valuable lead compound for the development of potential therapeutics against acute myeloid leukemia. XY153 demonstrated good metabolic stability in vitro. All liver microsome assays were performed by Medicilon

2023-07-17

Pan-bromodomain and extra terminal (Pan-BET) inhibitors show profound efficacy but exhibit pharmacology-driven toxicities in clinical trials. The representative Compound 8l (XY153), a novel BD2-selective BET inhibitor, potently binds to BRD4 BD2 with an IC50 value of 0.79 nM. XY153 displayed potent antiproliferative activity against multiple tumor cell lines. XY153 also demonstrated good metabolic stability in vitro. These data indicate that XY153 may serve as a new and valuable lead compound for the development of potential therapeutics against acute myeloid leukemia (AML). All liver microsome assays were performed by Medicilon.